Author information from the last article
Sigrun Halvorsen er dr.med., spesialist i indremedisin og i hjertesykdommer, avdelingsleder ved Hjertemedisinsk avdeling, Oslo universitetssykehus, Ullevål og professor i kardiologi ved Universitetet i Oslo.
Articles by Sigrun Halvorsen
Secondary prevention with beta-blockers after myocardial infarction
- John Munkhaugen,
- Arnhild Bakken,
- Anna Meta Dyrvig Kristiansen,
- Thor Edvardsen,
- Rune Wiseth,
- Terje Kristian Steigen,
- Henrik Schirmer,
- Alf-Inge Larsen,
- Jarle Jortveit,
- Kjell Vikenes,
- Sigrun Halvorsen,
- Dan Atar
02.02.2026:
Recent studies and meta-analyses show that treatment with beta-blockers improves prognosis after myocardial infarction in patients with mildly reduced left ventricular function, but not in patients with normal function who have no other indications for beta-blockers. The results of these new studies...
Secondary prevention in myocardial infarction patients with known coronary artery disease
- Jarle Jortveit,
- John Munkhaugen,
- Anete Kaldal,
- Sigrun Halvorsen
15.12.2025:
Patients with established coronary artery disease (CAD) have an increased risk of new cardiovascular events, including myocardial infarction and premature death (1, 2). There is a very well-documented risk-reducing effect from implementing lifestyle measures and treatment with antiplatelet drugs...
More STEMI patients should receive thrombolytic therapy
- Kaare Harald Bønaa,
- Olav Magne Leiren,
- Bjørn Inge Våga,
- Gunnar Vangberg,
- Ragna Elise Støre Govatsmark,
- Andreas Kristensen,
- Erik Jerome Stene Packer,
- Rune Wiseth,
- Lars Aaberge,
- Sigrun Halvorsen,
- Ole Christian Mjølstad
06.06.2025:
In patients with an ST-elevation myocardial infarction (STEMI) on ECG, the occluded coronary artery must be opened as quickly as possible. This can prevent myocardial damage, complications and death. Many patients in Norway are treated too late. Many STEMI patients do not receive reperfusion therapy...
Personalised cardiovascular disease prevention in the new guidelines
- Elise Sverre,
- Sigrun Halvorsen,
- Maja-Lisa Løchen,
- John Munkhaugen
23.11.2022:
The new European Guidelines for cardiovascular disease prevention have introduced a stepwise approach with lifestyle measures at the core. The use of drug treatment is recommended based on a risk assessment also taking into consideration the patient's frailty, comorbidities and own preferences. New...
Pharmacy-dispensed drugs for secondary prevention after myocardial infarction
- Jarle Jortveit,
- Sigrun Halvorsen,
- Jørund Langørgen
09.03.2020:
Each year, approximately 13 000 Norwegians are hospitalised with acute myocardial infarction (1). Patients with established coronary artery disease are at increased risk of further cardiovascular events and premature mortality (2). Patients with a history of myocardial infarction are advised to...
Gender differences in the assessment and treatment of myocardial infarction
- Jarle Jortveit,
- Ragna Elise Støre Govatsmark,
- Jørund Langørgen,
- Torstein Hole,
- Jan Mannsverk,
- Siv Olsen,
- Cecilie Risøe,
- Sigrun Halvorsen
23.08.2016:
Each year, some 13 000 Norwegians are admitted to Norwegian hospitals with acute myocardial infarction (1). Several studies have shown that women may have less clear symptoms and clinical findings, wait longer for treatment, less frequently undergo invasive assessment and receive less secondary...
Myocardial infarction in Norway in 2013
- Jarle Jortveit,
- Ragna Elise Støre Govatsmark,
- Tormod Aarlott Digre,
- Cecilie Risøe,
- Torstein Hole,
- Jan Mannsverk,
- Stig Arild Slørdahl,
- Sigrun Halvorsen
14.10.2014:
Cardiovascular diseases constitute the most common cause of hospitalisation in Norway (1). Although the mortality rate for these diseases has fallen in Norway in recent years, ischaemic heart disease is still one of the most common causes of death (2). Up until 2012 there was no national quality...